Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy
September 24, 2013 08:07 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
JAIDS Study by Argos Therapeutics Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients
September 16, 2013 08:07 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present at the Stifel Healthcare Conference 2013
September 06, 2013 09:45 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy
August 27, 2013 08:00 ET
|
Argos Therapeutics
DURHAM, N.C., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Identifies Topical Formulation for Prolonged Graft Survival in Corneal Transplants
August 15, 2013 08:03 ET
|
Argos Therapeutics
DURHAM, N.C., Aug. 15, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to...
Argos Therapeutics Announces Plans for HIV Eradication Study
July 01, 2013 15:03 ET
|
Argos Therapeutics
DURHAM, N.C., July 1, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Leading HIV Researchers and Argos Therapeutics Highlight Importance of Immunotherapy in HIV Eradication Efforts
June 13, 2013 09:59 ET
|
Argos Therapeutics
DURHAM, N.C., June 13, 2013 (GLOBE NEWSWIRE) -- In conjunction with the U.S. Food and Drug Administration's (FDA) June 14th Public Meeting on HIV Patient-Focused Drug Development and HIV Cure...
Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy
June 10, 2013 11:03 ET
|
Argos Therapeutics
DURHAM, N.C., June 10, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present at the Sachs Cancer Bio Partnering Forum
May 20, 2013 08:05 ET
|
Argos Therapeutics
DURHAM, N.C., May 20, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present at the 12th Annual Needham Healthcare Conference
April 29, 2013 09:01 ET
|
Argos Therapeutics
DURHAM, N.C., April 29, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...